Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. KEGG DRUG DrugBank Drug (Description in trials) KEGG GENES KEGG PATHWAY Disease ID
1 Lamivudine [1] Lamivudine[4] COMBIVIR; Epivir; Lamivudine; Triumeq; --[8] 2, 26, 42, 46, 135, 256, 265, 325
2 Zidovudine [1] Zidovudine[3] COMBIVIR; Retrovir; Zidovudine; --[7] 25, 26, 94, 135, 265, 325, 331
3 Emtricitabine [1] Emtricitabine[2] Emtricitabine; TRUVADA; --[4] 25, 93, 265, 325
4 Tenofovir [1] Tenofovir[1] Tenofovir; --[6] 2, 13, 25, 93, 265, 325
5 Abacavir [1] Abacavir[4] Abacavir; Abacavir sulfate; Triumeq; Ziagen; --[5] 2, 135, 256, 265, 325
6 Baricitinib [1] Baricitinib[2] BARICITINIB; OLUMIANT; [2] JAK1,
JAK2 💬		[35] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬[13] 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325